SCM
JNCE

Silverarc Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Silverarc Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-248,347
Closed -$1.69K – 96
2022
Q1 		$1.69K Buy
248,347
+2,518
+1% +$17.9K 0.8% 35
2021
Q4 		$2.05M Buy
245,829
+37,270
+18% +$307K 0.92% 39
2021
Q3 		$1.55M Sell
208,559
-42,085
-17% -$261K 0.9% 41
2021
Q2 		$1.7K Sell
250,644
-99,356
-28% -$825K 0.83% 48
2021
Q1 		$3.6M Sell
350,000
-56,665
-14% -$621K 2.01% 17
2020
Q4 		$2.85M Buy
+406,665
New +$3.17M 1.74% 22

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $950M AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.9B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $77B AUM 50.57% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return